Sep 25 - Oct 31
New ARPA-H External Funding: THRIVE – Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines
Extramural Funding
THRIVE: Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines
One in ten people, mostly newborns, infants, and children, suffer from chronic genetic diseases that progress rapidly, cause severe disability, reduce quality of life, and may even result in premature loss of life. Most urgent are rare diseases, affecting 30 million Americans. Despite their high unmet needs, about 95% of rare diseases have no approved treatments. Lifetime medical and other costs of rare diseases can be substantial and create financial hardship for families.
THRIVE aims to make personalized and affordable cures available to all rare disease patients. The program intends to develop pioneering integrated platform technologies to accelerate precision genetic medicines (PGMs) and provide single-intervention precision treatments to slow, reverse, or prevent chronic diseases at the genetic level. THRIVE is designed to optimize affordability, scalability, and sustainability of lifesaving PGMs for patients through existing regional treatment centers and virtual clinics. This will allow patients to be seen and treated where they live.
Key Details:
One in ten people, mostly newborns, infants, and children, suffer from chronic genetic diseases that progress rapidly, cause severe disability, reduce quality of life, and may even result in premature loss of life. Most urgent are rare diseases, affecting 30 million Americans. Despite their high unmet needs, about 95% of rare diseases have no approved treatments. Lifetime medical and other costs of rare diseases can be substantial and create financial hardship for families.
THRIVE aims to make personalized and affordable cures available to all rare disease patients. The program intends to develop pioneering integrated platform technologies to accelerate precision genetic medicines (PGMs) and provide single-intervention precision treatments to slow, reverse, or prevent chronic diseases at the genetic level. THRIVE is designed to optimize affordability, scalability, and sustainability of lifesaving PGMs for patients through existing regional treatment centers and virtual clinics. This will allow patients to be seen and treated where they live.
Key Details:
- Notice ID: ARPA-H-SOL-25-122
- Solution Summary Due: October 31, 2025 A summary is required to submit a full proposal.
- Full Proposal Due: December 19, 2025 Encouraged submissions preferred. Additional details will be provided in a solution summary feedback letter.
- Full RFP: Found HERE